Hyperion Therapeutics to Present at Upcoming Investor Conferences in November

        Print
| Source: Hyperion Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at two investor conferences in November:

Lazard Capital Markets 9th Annual Healthcare Conference in New York
Wednesday, November 14 at 2:30 p.m. ET.
 
Piper Jaffray 24th Annual Healthcare Conference in New York
Tuesday, November 27 at 12:30 p.m. ET.

Donald J. Santel, Chief Executive Officer of Hyperion, will provide a company overview. To access the live webcasts and subsequent archived recordings, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics

Hyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.

Shari Annes, Investor Relations
Cell: 650-888-0902